Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/ KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer

被引：0

作者：

Randall, Leslie ^{[1
]}

Sukhin, Vladyslav ^{[2
]}

Colombo, Nicoletta ^{[3
,4
]}

Korach, Jacob ^{[5
]}

Matsumoto, Takashi ^{[6
]}

Lalondrelle, Susan ^{[7
]}

Vizkeleti, Julia ^{[8
]}

Samouelian, Vanessa ^{[9
]}

Salani, Ritu ^{[10
]}

Salman, Pamela ^{[11
]}

Nogueira-Rodrigues, Angelica ^{[12
]}

Ayhan, Ali ^{[13
]}

Frentzas, Sophia ^{[14
,15
]}

Cueva, Juan ^{[16
]}

Kim, Yong-Man ^{[17
]}

Petru, Edgar ^{[18
]}

Milla, Dency Pilar ^{[19
]}

Sehouli, Jalid ^{[20
]}

Saevets, Valeriya ^{[21
]}

Yamada, Karin ^{[22
]}

Li, Kan ^{[23
]}

Szamreta, Elizabeth ^{[22
]}

Nguyen, Allison Martin ^{[22
]}

Pignata, Sandro ^{[24
]}

Lorusso, Domenica ^{[25
]}

机构：

[1] Virginia Commonwealth Univ, Richmond, VA USA

[2] Grigoriev Inst Med Radiol & Oncol, Kharkiv, Ukraine

[3] Univ Milano Bicocca, Milan, Italy

[4] European Inst Oncol IRCCS, Milan, Italy

[5] Sheba Med Ctr, Tel Aviv, Israel

[6] Ehime Univ, Matsuyama, Ehime, Japan

[7] Royal Marsden, London, England

[8] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary

[9] Univ Montreal, Montreal, PQ, Canada

[10] Univ Calif Los Angeles, Los Angeles, CA USA

[11] Oncovida Canc Ctr, Santiago, Chile

[12] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil

[13] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkiye

[14] Monash Hlth, Melbourne, Vic, Australia

[15] Monash Univ, Melbourne, Vic, Australia

[16] Hosp Clin Univ Santiago Compostela, Dept Med Oncol, Santiago De Compostela, Spain

[17] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[18] Med Univ Graz, Graz, Austria

[19] Hosp Nacl Guillermo Almenara Irigoyen, Lima, Peru

[20] Charite Univ Med Berlin, Berlin, Germany

[21] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Chelyabinsk, Russia

[22] Merck & Co Inc, Rahway, NJ 07065 USA

[23] Merck & Co Inc, N Wales, PA USA

[24] Inst Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[25] Univ Cattolica Sacro Cuore, Rome, Italy

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S9 / S9

页数：1

共 50 条

[31] Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Garassino, Marina C.
Gadgeel, Shirish
Esteban, Emilio
Felip, Enriqueta
Speranza, Giovanna
Domine, Manuel
Hochmair, Maximilian
Powell, Steve
Cheng, Susanna Yee-Shan
Bischoff, Helge G.
Peled, Nir
Reck, Martin
Hui, Rina
Garon, Edward B.
Boyer, Michael
Wei, Ziwen
Burke, Thomas
Pietanza, M. Catherine
Rodriguez-Abreu, Delvys
LANCET ONCOLOGY, 2020, 21 (03): : 387 - 397
[32] CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Matsubara, N.
Agarwal, N.
Smith, M. R.
Mckay, R. R.
Todenhofer, T.
Piulats Rodriguez, J. M.
Chung, K. L.
Heirich, D.
Sherwood, S.
Schaverien, C.
Fasnacht, N.
Lithio, A.
Nacerddine, K.
Zhang, T.
ANNALS OF ONCOLOGY, 2023, 34 : S1582 - S1583
[33] Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
Novello, Silvia
Kaiser, Rolf
Mellemgaard, Anders
Douillard, Jean-Yves
Orlov, Sergey
Krzakowski, Maciej
von Pawel, Joachim
Gottfried, Maya
Bondarenko, Igor
Liao, Meilin
Barrueco, Jose
Gaschler-Markefski, Birgit
Griebsch, Ingolf
Palmer, Michael
Reck, Martin
EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) : 317 - 326
[34] ANALYSIS OF PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Novello, Silvia
Mellemgaard, Anders
Kaiser, Rolf
Douillard, Jean-Yves
Orlov, Sergei
Krzakowski, Maciej
Von Pawel, Joachim
Gottfried, Maya
Bondarenko, Igor
Liao, Meilin
Barrueco, Jose
Gaschler-Markefski, Birgit
Griebsch, Ingolf
Reck, Martin
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1207 - S1207
[35] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Chehrazi-Raffle, Alex
Morgans, Alicia K.
Gschwend, Jurgen E.
Shore, Neal D.
Ross, Ashley
Feng, Felix Y.
Hope, Thomas A.
Trandafir, Lucia
Kuss, Iris
Le Berre, Marie-Aude
Joensuu, Heikki
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS254 - TPS254
[36] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Morgans, Alicia K.
Niazi, Tamim
Shore, Neal D.
Gschwend, Juergen E.
Ross, Ashley
Hope, Thomas A.
Chehrazi-Raffle, Alex
Supiot, Stephane
Barthelemy, Philippe
Roder, Andreas
Gomes, Andrea Juliana
Imbroda, Bernardo Herrera
Gratton, Matthieu
Ruiz, Carmen Belen Congregado
Joensuu, Heikki
Dimova-Dobreva, Miryana
Le Berre, Marie-Aude
Kuss, Iris
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS432 - TPS432
[37] Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study
Yang, Yue
Xu, Jianhua
Xu, Jian
Li, Xingfu
Hu, Jiankang
Li, Xiangpei
Zhang, Xiao
He, Dongyi
Bao, Chunde
Li, Zhijun
Wang, Guochun
Zerbini, Cristiano A. F.
Spindler, Alberto J.
Kannowski, Carol L.
Wu, Hanjun
Ji, Fei
Zhan, Lujing
Liu, Mengru
Li, Zhanguo
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
[38] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)
Taplin, Mary-Ellen
Gleave, Martin
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Cheng, Shinta
Brookman-May, Sabine Doris
Lopez-Gitlitz, Angela
Kibel, Adam S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[39] Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study
Bourhis, J.
Sun, X.
Pointreau, Y.
Sire, C.
Le Tourneau, C.
Coutte, A.
Kaminsky-Forrett, M-C.
Alfonsi, M.
Boisselier, P.
Martin, L.
Delord, J-P.
Clatot, F.
Miroir, J.
Rolland, F.
Crompton, P.
Brienza, S.
Szyldergemajn, S. A.
Even, C.
Tao, Y.
ANNALS OF ONCOLOGY, 2019, 30 : 902 - 902
[40] LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.
Burtness, Barbara
Bourhis, Jean
Vermorken, Jan Baptist
Dai, Luyan
Lind, Charlotte
Ehrnrooth, Eva
Cohen, Ezra E. W.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →